Steatohepatitis
22
2
3
11
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.6%
3 terminated out of 22 trials
78.6%
-7.9% vs benchmark
0%
0 trials in Phase 3/4
18%
2 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (22)
Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
Diagnosis and Quantification of Hepatic Steatosis Using Near-infrared Spectroscopy
Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
Fatty Liver and Ectopic Fat in Overweight and Obese Patients
PET-MR Study of Fatty Liver
Integrated Approaches for Identifying Molecular Targets in Liver Disease
Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
Randomized Clinical Trial; Medical vs Bariatric Surgery for Adolescents (13-16 y) With Severe Obesity
A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection
Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV
Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy
Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients
Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease
Prognostic Indicators as Provided by the EPIC ClearView